

LifeSci Biotechnology Clinical Trials Index

3/5/2024

Effective at the market close on Wednesday, March 6, 2024, **AMAM** will be removed from the **LifeSci Biotechnology Clinical Trials Index** and its value will be redistributed to the remaining index components based on their weights.

- On January 8, 2024, Ambrx announced that it would be acquired by Johnson & Johnson for \$28.00/share in cash.